spacer
The Healthcare Sales & Marketing Network celebrates 21 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Vidaza 

 HSMN NewsFeed - 5 Sep 2018
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Oct 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Sep 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Apr 2014
MEI Pharma Adds Former VC David Urso as Senior Vice President of Corporate Development and General Counsel
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jan 2010
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Nov 2009
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2008
Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Aug 2008
VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Aug 2008
Sucampo Pharmaceuticals Announces Key Management and Board Appointments at its European Affiliate
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2008
Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2008
VIDAZA(R) Continues to Show Significant Overall Survival Benefit When Compared with Conventional Care Regimens Across the EU
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2008
Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2008
Celgene Completes $2.9 Billion Acquisition of Pharmion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Feb 2008
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2008
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2008
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2008
MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Feb 2008
EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jan 2008
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jan 2008
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2007
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 9 Nov 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2007
GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2007
Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2007
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2007
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Aug 2007
Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 21 Aug 2007
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Aug 2007
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jun 2007
Pharmion Submits European Marketing Authorization Application for Satraplatin in Combination With Prednisone for the Treatment of Patients With Metastatic Hormone-Refractory Prostate Cancer Who Have Failed Prior Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Mar 2007
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Feb 2007
NCCN Updates Myelodysplastic Syndromes (MDS) Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2007
Pharmion Corporation Announces FDA Approval of Vidaza NDA Supplement for IV Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jan 2007
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Dec 2006
New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Nov 2006
Pharmion and Nippon Shinyaku Announce Licensing Agreement for Vidaza(R) in Japan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 1 Nov 2006
Pharmion Corporation Announces Enrollment of First Patient Into Vidaza(R) Patient Registry
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2006
Pharmion Corporation and GPC Biotech Announce Positive Results from the Satraplatin Pivotal Phase 3 Trial and Achievement of the Progression-Free Survival Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2006
Affymax Appoints Jeffrey H. Knapp as Chief Commercialization Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2006
Pharmion Corporation Announces FDA Acceptance of Vidaza NDA Supplement for IV Administration for Filing and Grants Six Month Review Goal
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 May 2006
Pharmion Appoints Andrew Allen as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2006
Pharmion Announces Start of Phase 1 Trial Evaluating Satraplatin Plus Xeloda(R) in Patients With Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Apr 2006
Independent Data Monitoring Board Recommends That Satraplatin Phase 3 Trial Continue as Planned
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Mar 2006
Pharmion Corporation Announces Submission of Vidaza NDA Supplement for IV Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Feb 2006
Scientific Advice From European Regulatory Authorities Confirms Progression-Free Survival Data Acceptable for Satraplatin Submission
Biopharmaceuticals Oncology Regulatory
Return to NewsFeed  

 Additional items found! 9

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 9 additional stories matching:
Vidaza
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.